BioNTech SE (BNTX) said Monday it will continue executing its strategy in 2026 to evolve into a multi-product oncology company, with the year expected to be catalyst-rich as late-stage programs advance across immunomodulators, antibody-drug conjugates, and mRNA-based cancer therapies.
